Fischer Medical Ventures Ltd

Fischer Medical Ventures Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the trading window for its equity shares will be closed for promoters, directors, and designated persons from October 01, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026.

Fischer Medical Ventures Limited, formerly Fischer Chemic Limited, announced that its material wholly-owned subsidiaries, Time Medical International Ventures (India) Private Limited, Flynncare Health Innovations Private Limited, and FMV Global Innovation Pte. Ltd., have issued equity shares via rights issues. Time Medical International Ventures issued 15,603 shares at Rs 7,370.25 per share, Flynncare Health Innovations issued 1,507 shares at Rs 82,943.48 per share, and FMV Global Innovation Pte. Ltd. issued 53 shares at Rs 48,83,552.64 per share. The company’s board approved investments in these rights issues, with total costs amounting to Rs 11,50,00,000 for Time Medical, Rs 12,50,00,000 for Flynncare, and Rs 26,00,00,000 for FMV Global Innovation.

Fischer Medical Ventures Limited, formerly Fischer Chemic Limited, announced the appointment of David Yeow as an additional independent director with effect from September 3, 2026, for a term of five years, subject to shareholder approval. The company also reconstituted its audit committee following Yeow’s appointment, and will hold its 33rd Annual General Meeting on September 29, 2026, via video conferencing, while the company’s share transfer books will be closed from September 23, 2026, to September 29, 2026.

Fischer Medical Ventures Limited, formerly Fischer Chemic Limited, informed the BSE Limited and National Stock Exchange of India Ltd. that the register of members and share transfer books will remain closed from September 23, 2026, to September 29, 2026, for the Annual General Meeting scheduled on September 29, 2026, with a record date of September 22, 2026, to determine dividend and voting rights, and a cut-off date of September 4, 2026, for dispatch of the Annual General Meeting notice.

Fischer Medical Ventures Limited announced that its Board of Directors approved the allotment of 4,54,210 equity shares with a face value of Re. 1 each at an issue price of Rs 23.40 per share, including a premium of Rs 22.40, to FMV Holdings Pte Ltd, a promoter entity, upon the exercise of warrants. The company received Rs 79,71,385.50 in consideration for the allotment.

Fischer Medical Ventures Limited announced that its board approved the allotment of 2,05,05,909 equity shares with a face value of Re. 1 each at an issue price of Rs. 23.40 per share, including a premium of Rs. 22.40 per share, following the conversion of warrants, receiving Rs. 35,98,78,702.95 in consideration. The allottees include Mr. Shankar Varadharajan, FMV Holdings Pte Ltd, and Vritti Hitesh Kawa, with Mr. Shankar Varadharajan converting 60,00,000 warrants, FMV Holdings Pte Ltd converting 73,35,909 warrants, and Vritti Hitesh Kawa converting 71,70,000 warrants.

Fischer Medical Ventures Limited announced that its board approved the allotment of 1,42,78,217 equity shares with a face value of Re. 1 each at an issue price of Rs 23.40 per share, including a premium of Rs 22.40, following the conversion of warrants. The company received Rs 25,05,82,708.35 in consideration for the allotment, with Mr. Shankar Varadharajan, FMV Holdings Pte Ltd, and Vikasa India Eif I Fund being the allottees.

Fischer Medical Ventures Limited informed the BSE Limited and National Stock Exchange of India Ltd. that its board approved the allotment of 66,31,664 equity shares with a face value of Re. 1 each at an issue price of Rs 23.40 per share, including a premium of Rs 22.40, upon the exercise of convertible warrants by promoters and a promoter group entity, FMV Holdings Pte Ltd, receiving Rs 11,63,85,703 in consideration.

Fischer Medical Ventures Limited announced that its Board of Directors approved the allotment of 23,00,000 equity shares with a face value of Re. 1 each at an issue price of Rs 23.40 per share, including a premium of Rs 22.40, to Mr. Shankar Varadharajan, a promoter, upon the exercise of convertible warrants, resulting in a total consideration received of Rs 4,03,65,000.

Fischer Medical Ventures Limited will hold a board meeting on August 14, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Ltd. The trading window for the company's equity shares is currently closed for designated persons and will remain so until 48 hours after the financial results are declared.